Ramsay Stattman Vela & Price Inc. Sells 4,321 Shares of Stryker Corporation $SYK

Posted by Stanley Muller on Jul 10th, 2026

Ramsay Stattman Vela & Price Inc. trimmed its stake in Stryker Corporation (NYSE:SYK – Free Report) by 9.0% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 43,548 shares of the medical technology company’s stock after selling 4,321 shares during the quarter. Stryker makes up about 2.8% of Ramsay Stattman Vela & Price Inc.’s investment portfolio, making the stock its 9th largest holding. Ramsay Stattman Vela & Price Inc.’s holdings in Stryker were worth $14,309,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of SYK. Czech National Bank grew its position in Stryker by 3.9% in the 4th quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock worth $31,898,000 after purchasing an additional 3,366 shares during the last quarter. Daymark Wealth Partners LLC raised its holdings in shares of Stryker by 436.0% during the fourth quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock valued at $16,119,000 after buying an additional 37,307 shares during the last quarter. Varma Mutual Pension Insurance Co raised its holdings in shares of Stryker by 10.5% during the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after buying an additional 5,100 shares during the last quarter. Wealthcare Advisory Partners LLC boosted its position in shares of Stryker by 265.2% during the fourth quarter. Wealthcare Advisory Partners LLC now owns 9,328 shares of the medical technology company’s stock worth $3,278,000 after buying an additional 6,774 shares during the period. Finally, Sei Investments Co. boosted its position in shares of Stryker by 1.8% during the third quarter. Sei Investments Co. now owns 427,634 shares of the medical technology company’s stock worth $158,090,000 after buying an additional 7,655 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SYK. Barclays decreased their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Needham & Company LLC reduced their price target on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Wells Fargo & Company decreased their price target on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Weiss Ratings cut Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Finally, Sanford C. Bernstein set a $410.00 price target on Stryker in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $392.87.

View Our Latest Research Report on Stryker

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 323,264 shares of company stock valued at $100,659,489 over the last 90 days. 4.60% of the stock is currently owned by corporate insiders.

Stryker Price Performance

Shares of NYSE:SYK opened at $326.87 on Friday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The stock has a market cap of $125.31 billion, a price-to-earnings ratio of 37.83, a PEG ratio of 2.09 and a beta of 0.77. The stock’s 50 day moving average price is $309.82 and its 200 day moving average price is $338.02. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25.

Stryker (NYSE:SYK – Get Free Report) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the company earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio is 40.74%.

Stryker Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.